Loading stock data…
Becton, Dickinson and Company (BDX)
$179.10-5.64 (-3.05%)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Becton, Dickinson and Company in the Healthcare sector is trading at $179.10 with a market capitalization of $50.3B. Wall Street consensus targets $195.67 (12 analysts), implying a +9.2% move over the next 12 months. The stock is currently 7% below its 52-week high of $193.07, remaining 12.8% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +9.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.71B↓ | $5.25B↓ | $5.89B↑ | $5.51B↑ | $4.48B |
| Gross Profit | $2.15B↓ | $2.41B↓ | $2.80B↑ | $2.63B↑ | $1.86B |
| Operating Income | $626.00M↓ | $662.00M↓ | $826.00M↓ | $979.00M↑ | $477.00M |
| Net Income | -$311.00M↓ | $382.00M↓ | $493.00M↓ | $574.00M↑ | $308.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$50.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
31.96
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.09%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.85%
Volume
Today's trading volume
1.80M
Recent News
BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure
Baxter raises its 2026 sales and earnings outlook after strong Q2 growth, though manufacturing costs, tariffs and pricing pressure margins.
How Much Upside Can BSX Stock's Growth Deliver?
While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.
How Is Becton, Dickinson and Company's Stock Performance Compared to Other Medical Devices Stocks?
Becton, Dickinson and Company has notably outperformed the Medical Devices industry over the past year, and analysts are cautiously optimistic about the stock’s prospects.
3 Dividend Stocks From a Value Pro
A First Eagle value investor likes Noble, Kesko, and Becton Dickinson for their dividends and growth potential.
Becton Dickinson (BDX) Becomes Founding Sponsor Of Hazardous Drug Data Consortium
Becton Dickinson (NYSE:BDX) has become a founding sponsor of a new Medicinal Hazard Data Standardization Consortium focused on hazardous drug information. The global initiative aims to create standardized Medicinal Hazard Data Sheets to reduce data fragmentation and support safer handling of hazardous medicines for healthcare workers. Several major healthcare companies are joining BD in the consortium, which is expected to influence future regulatory and clinical best practice...